Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082888
Status:
COMPLETED
Last Update Posted:
2020-04-13
First Post:
2004-05-14
Brief Title:
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Anaplastic Large Cell Lymphoma |
| Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue |
| Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma |
| Nodal Marginal Zone Lymphoma |
| Recurrent Adult Hodgkin Lymphoma |
| Recurrent Adult T-Cell LeukemiaLymphoma |
| Recurrent Grade 1 Follicular Lymphoma |
| Recurrent Grade 2 Follicular Lymphoma |
| Recurrent Grade 3 Follicular Lymphoma |
| Recurrent Mantle Cell Lymphoma |
| Recurrent Non-Hodgkin Lymphoma |
| Recurrent Small Lymphocytic Lymphoma |
| Splenic Marginal Zone Lymphoma |
Keywords: